New cocktail of drugs tested for Tough-to-Treat colon cancer

NCT ID NCT07011550

Terminated Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This phase 2 trial is testing whether a combination of four drugs—BMS-986340, nivolumab, trifluridine/tipiracil, and bevacizumab—can help control advanced colorectal cancer that has not responded to standard treatments. The study is for people with a specific type called microsatellite-stable colorectal cancer. Only 7 participants were planned, but the trial is currently suspended.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BMS-986340, nivolumab, trifluridine/tipiracil, and bevacizumab
What this could lead to: If it works, this could offer a new treatment option for people with a hard-to-treat form of colorectal cancer that has stopped responding to standard therapies.
What could go wrong: This is a very small, early-phase trial (only 7 participants planned) that is currently suspended. The combination may cause significant side effects, and it is unknown if it will be effective enough to move forward.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BEVACIZUMAB are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BEVACIZUMAB MICROSATELLITE STABLE COLORECTAL CANCER NIVOLUMAB STANDARD OF CARE

Contacts and locations

Locations

MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.